Gland Pharma signs CDMO manufacturing and supply pact with USD 90–100 million annual revenue potential from 2029
AI Market Summary
Gland Pharma signed a CDMO manufacturing and supply agreement for 55 sterile injectable SKUs, with annualized revenue potential of USD 90–100m once commercialized, but revenues are expected to start only in 2029. The deal improves long-term visibility and positions the company as an end-to-end sterile injectables partner, while a separate expansion with Neuland adds targeted sterile API capacity. Near-term market impact is likely limited given the long execution timeline.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.24%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
India’s Gland Pharma has signed a CDMO agreement with an undisclosed leading global pharmaceutical company to manufacture and supply 55 sterile injectable SKUs spanning oncology and non-oncology products. The portfolio includes vial, lyo, ampoules and prefilled syringe (PFS) presentations, with work covering technology transfer through long-term commercial supply. The partnership is expected to start generating revenue in calendar year 2029, with annualized revenue potential estimated at USD 90–100 million once all products are commercialized.
